IOR-T3
IOR-T3 is a monoclonal antibody targeting CD3, with biological activities related to T cell activation regulation. IOR-T3 uses its variable region to competitively engage surface CD3 on lymphocytes and trigger robust T cell proliferation and activation. IOR-T3 and its derivatives can be used in studies related to acute transplant rejection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
IOR-T3 (1 h) potently binds to CD3 on human PBMCs, with equivalent antigen-binding capacity to its chimeric variants T3q and T3q(Ala=Ala)[1].
IOR-T3 (70-100 μg/mL; 7 days) does not inhibit the growth of human non-small-cell lung carcinoma H125 cells when used at 100 μg/mL for 7 days[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human non-small-cell lung carcinoma H125 cells
-
Concentration:70, 90, 100 μg/mL
-
Incubation Time:7 days
-
Result:Showed no inhibitory effect on H125 cell growth, with cell protein content remaining at 100% of control levels.
CD3E
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Hinojosa LE, et al. Construction of a recombinant non-mitogenic anti-human CD3 antibody. Hybridoma (Larchmt). 2010;29(2):115-124. [Content Brief]
[2]. Suarez Pestana E, et al. Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). Br J Cancer. 1997;75(2):213-220. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IOR-T3 Related Classifications
HY-P992390 Related Classifications
Powered by Bioz